Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer

BACKGROUND: Genomic biomarkers that predict response to anti‐PD1 therapy in prostate cancer are needed. Frameshift mutations are predicted to generate more neoantigens than missense mutations; therefore, we hypothesized that the number or proportion of tumor frameshift mutations would correlate with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sena, Laura A., Fountain, Julia, Isaacsson Velho, Pedro, Lim, Su Jin, Wang, Hao, Nizialek, Emily, Rathi, Nityam, Nussenzveig, Roberto, Maughan, Benjamin L., Velez, Miguel Gonzalez, Ashkar, Ryan, Larson, Amanda C., Pritchard, Colin C., Adra, Nabil, Bryce, Alan H., Agarwal, Neeraj, Pardoll, Drew M., Eshleman, James R., Lotan, Tamara L., Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873327/
https://www.ncbi.nlm.nih.gov/pubmed/33215787
http://dx.doi.org/10.1002/onco.13601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873327/
https://www.ncbi.nlm.nih.gov/pubmed/33215787
http://dx.doi.org/10.1002/onco.13601

Ejemplares similares